Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high‐risk donor seropositive/recipient seronegative heart transplant recipients

Cytomegalovirus infection in heart transplantation: A single center experience

(2018) Ignacio A. Echenique et al.   Transplant Infectious Disease

Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin

(2018) Mari Eriksson et al.   Transplant Infectious Disease

Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era - a retrospective study

(2018) Johannes Goekler et al.   TRANSPLANT INTERNATIONAL

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

(2018) Camille N. Kotton et al.   TRANSPLANTATION

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

(2016) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients

(2015) Inger Johansson et al.   BMC INFECTIOUS DISEASES

Cytomegalovirus in Solid Organ Transplantation

(2013) R. R. Razonable et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation

(2013) Scott M. Palmer   ANNALS OF INTERNAL MEDICINE

High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy

(2013) Heli Harvala et al.   JOURNAL OF MEDICAL VIROLOGY

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

(2012) Andreas Doesch et al.   Drug Design Development and Therapy

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial

(2011) C. Ashley Finlen Copeland et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Preemptive Versus Sequential Prophylactic-Preemptive Treatment Regimens for Cytomegalovirus in Renal Transplantation: Comparison of Treatment Failure and Antiviral Resistance

(2010) Martha T. van der Beek et al.   TRANSPLANTATION

Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

(2010) Atul Humar et al.   TRANSPLANTATION

Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients

(2010) Noémie Boillat Blanco et al.   TRANSPLANTATION

Prophylactic Therapy With Valgancyclovir in High-Risk (Cytomegalovirus D+/R−) Liver Transplant Recipients: A Single-Center Experience

(2009) M. Montejo et al.   TRANSPLANTATION PROCEEDINGS

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

(2008) D. J. Winston et al.   BLOOD

High Incidence of Cytomegalovirus Disease in D+/R− Heart Transplant Recipients Shortly After Completion of 3 Months of Valganciclovir Prophylaxis

(2008) Sachin Gupta et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION